Trillium Therapeutics Inc. (TRIL): Price and Financial Metrics
TRIL Price/Volume Stats
| Current price | $18.44 | 52-week high | $20.96 |
| Prev. close | $17.97 | 52-week low | $5.80 |
| Day low | $17.83 | Volume | 26,174,700 |
| Day high | $18.49 | Avg. volume | 1,866,404 |
| 50-day MA | $17.69 | Dividend yield | N/A |
| 200-day MA | $11.97 | Market Cap | 1.94B |
TRIL Stock Price Chart Interactive Chart >
Trillium Therapeutics Inc. (TRIL) Company Bio
Trillium Therapeutics develops therapies for the treatment of cancer. The company was founded in 2004 and is based in Toronto, Canada.
Latest TRIL News From Around the Web
Below are the latest news stories about Trillium Therapeutics Inc that investors may wish to consider to help them evaluate TRIL as an investment opportunity.
Trillium Therapeutics gets Canada, HSR approval for sale to PfizerTrillium Therapeutics (NASDAQ:TRIL) disclosed that applicable waiting periods under the Competition Act in Canada and HSR in the U.S. expired on Monday in regards to its $2.3B sale to Pfizer (NYSE:PFE). The closing of the transaction is expected to occur on or about tomorrow, according to an 8-K filing. Earlier,... |
7 of the Best Stocks to Buy for Their Free Cash FlowThese stocks to buy have a stable business outlook and robust free cash flows. |
Geode Capital Management LLC Acquires 766,327 Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL)Geode Capital Management LLC lifted its holdings in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 1,041.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 839,889 shares of the biotechnology companys stock after acquiring an additional 766,327 shares during [] |
Trillium Therapeutics Inc. (NASDAQ:TRIL) Given Consensus Recommendation of Hold by AnalystsShares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) have been given a consensus rating of Hold by the eight research firms that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers [] |
Trillium Therapeutics Inc. (NASDAQ:TRIL) Shares Purchased by Stifel Financial CorpStifel Financial Corp increased its holdings in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 56.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 81,650 shares of the biotechnology company’s stock after purchasing an additional 29,450 shares during the quarter. Stifel Financial Corp […] |
TRIL Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 99.78% |
| 5-year | 2,960.58% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 1,328.16% |
| 2019 | -39.77% |
Loading social stream, please wait...